MI PROFILE™

Final Report

CARIS LIFE SCIENCES

Patient

Name: Patient, Test
Date of Birth: XX/Mon/19XX
Sex: Male
Case Number: TN19-XXXXXX
Diagnosis: Mucinous adenocarcinoma

Specimen Information

Primary Tumor Site: Transverse colon
Specimen Site: Liver
Specimen ID: ABC-1234-XYZ
Specimen Collected: XX-Mon-2019
Completion of Testing: XX-Mon-2019

Ordered By

Ordering Physician, MD
Cancer Center
123 Main Street
Springfield, XY 12345, USA
1 (123) 456-7890

High Impact Results

BIOMARKER	METHOD	RESULT	THERAPY ASSOCIATION		BIOMARKER LEVEL*
Mismatch Repair Status	**IHC**	**Deficient**	**BENEFIT**	**nivolumab, nivolumab/ipilimumab combination, pembrolizumab**	**Level 1**
MSI	**NGS**	**High**			
BRAF	NGS	Mutated, Pathogenic Exon 15 | p.V600E	BENEFIT	Irinotecan + [cetuximab or panitumumab] + vemurafenib	Level 2
			LACK OF BENEFIT	vemurafenib/dabrafenib monotherapy	Level 3A
ERBB2 (Her2/Neu)	CISH	Amplified	BENEFIT	lapatinib, pertuzumab, trastuzumab	Level 3A

* Biomarker reporting classification: Level 1 - highest level of clinical evidence and/or biomarker association included on the drug label; Level 2 - strong evidence of clinical significance and is endorsed by standard clinical guidelines; Level 3 - potential clinical significance (3A - evidence exists in patient's tumor type, 3B - evidence exists in another tumor type).

Important Note

This patient has a potential NCI-MATCH Trial-eligible result. Please see Clinical Trial *see page 6*

Additional Results

CANCER TYPE RELEVANT BIOMARKERS		
Biomarker	Method	Result
NTRK1	RNA-Seq	Fusion Not Detected
NTRK2	RNA-Seq	Fusion Not Detected
NTRK3	RNA-Seq	Fusion Not Detected
Tumor Mutational Burden		High | 121 Mutations/Mb
ERBB2 (Her2/Neu)	NGS	Amplified
KRAS	NGS	Mutation Not Detected
NRAS	NGS	Mutation Not Detected
PIK3CA	NGS	Mutation Not Detected

CANCER TYPE RELEVANT BIOMARKERS (cont)		
Biomarker	Method	Result
PTEN	IHC	Positive | 1+, 55%
OTHER FINDINGS (see page 2 for additional results)		
Biomarker	Method	Result
PD-L1	SP142 IHC	Positive | 2+, 5%
FBXW7	NGS	Mutated, Pathogenic
		Exon 10 | p.R479Q
TSC1	NGS	Mutated, Pathogenic
		Exon 12 | p.N891fs
CCNE1	NGS	Amplified

4610 South 44th Place, Suite 100 • Phoenix, AZ 85040 • (888) 979-8669 • Fax: (866) 479-4925

Biomarker Results

This summary includes biomarkers most commonly associated with cancer. Complete details of all biomarkers tested can be found in the Appendix.

GENOMIC SIGNATURES		
Biomarker	**Method**	**Result**
Microsatellite Instability (MSI)	NGS	High
Tumor Mutational Burden (TMB)	NGS	

GENES TESTED WITH MUTATIONS/ALTERATIONS						
Gene	**Method**	**Variant Interpretation**	**Protein Alteration**	**Exon**	**DNA Alteration**	**Variant Frequency %**
BRAF	NGS	Mutated, Pathogenic	p.V600E	15	c.1799T>A	53
CCNE1	NGS	Amplified	-	-	-	-
ERBB2 (Her2/Neu)	CISH	Amplified	-	-	-	-
	NGS	Amplified	-	-	-	-
FBXW7	NGS	Mutated, Pathogenic	p.R479Q	10	c.1436G>A	32
FGFR1	NGS	Amplified	-	-	-	-
TSC1	NGS	Mutated, Pathogenic	p.N891fs	12	c.1148G>A	25

Unclassified alterations for DNA sequencing can be found in the Appendix.
Formal nucleotide nomenclature and gene reference sequences can be found in the appendix of this report.

Transcript ID and Variants of Unknown Significance can be found in the Appendix.

Other Findings

IMMUNOHISTOCHEMISTRY (IHC)			
Biomarker	**Result**	**Biomarker**	**Result**
MLH1	Negative | 0	PD-L1 (SP142)	Positive | 2+, 5%
MSH2	Positive | 1+, 40%	PMS2	Positive | 1+, 60%
MSH6	Positive | 1+, 30%	PTEN	Positive | 1+, 55%

Additional results continued on the next page. >

4610 South 44th Place, Suite 100 • Phoenix, AZ 85040 • (888) 979-8669 • Fax: (866) 479-4925
CLIA 03D1019490 • CAP 7195577 • ISO 15189:2012 • Zoran Gatalica, MD, DSc, Medical Director •

Clinical Trials Connector™

For a complete list of open, enrolling clinical trials visit MI Portal to access the **Clinical Trials Connector**. This personalized, real-time web-based service provides additional clinical trial information and enhanced searching capabilities, including, but not limited to:

- Location: filter by geographic area
- Biomarker(s): identify specific biomarkers associated with open clinical trials to choose from
- Drug(s): search for specific therapies
- Trial Sponsor: locate trials based on the organization supporting the trial(s)

Visit www.CarisMolecularIntelligence.com to view all matched trials. Therapeutic agents listed below may or may not be currently FDA approved for the tumor type tested.

NCI MATCH BIOMARKER SUMMARY			
Description	**Biomarker**	**Method**	**Investigational Agent(s)**
FGFR1,2,3,4 amplification / erdafitinib	FGFR1	NGS	erdafitinib

Please note that all NCI MATCH arms associated with this case may not be actively recruiting for enrollment, please contact NCI for confirmation.

Please note regarding amplification inclusion criteria: NCI MATCH gene amplification (CNA) thresholds are higher than the Caris reporting thresholds. As a result, only genes with amplification levels above the NCI MATCH threshold are shown in the table above.

TARGETED THERAPY CLINICAL TRIALS (337)			
Drug Class	**Biomarker**	**Method**	**Investigational Agent(s)**
Chk1/Chk2 inhibitors (4)	FBXW7	NGS	LY2606368
ERK inhibitors (1)	BRAF	NGS	BVD-523
FGFR-targeted therapy (3)	FGFR1	NGS	Debio1347, TAS120, sulfatinib
HER2-targeted therapy (17)	ERBB2 (Her2/Neu)	CISH	ado-trastuzumab emtansine (T-DM1), pertuzumab, trastuzumab
	ERBB2 (Her2/Neu)	NGS	
Immunomodulatory agents (204)	Mismatch Repair Status	IHC	MEDI4736, MK-3475, MPDL3280A, MSB0010718C, atezolizumab, avelumab, durvalumab, nivolumab, pembrolizumab
	MLH1	IHC	
	MSI	NGS	
	PD-L1	IHC	
	TMB	NGS	
MDM2 inhibitors (3)	TP53	NGS	ALRN-6924, DS-3032, RO5503781
MEK inhibitors (24)	BRAF	NGS	GDC-0973, PD0325901, XL518, selumetinib, trametinib
Multikinase inhibitors (18)	BRAF	NGS	AZD4547, BIBF1120 (nintedanib), GSK2118436 (dabrafenib), LGX818, ponatinib, sorafenib, vemurafenib
	FGFR1	NGS	

( ) = represents the total number of clinical trials identified by the Clinical Trials Connector for the provided drug class or table.

Please refer to the "Notes of Significance" section that may contain additional information regarding therapy associations.

Additional Clinical Trials Connector results continued on the next page. >

4610 South 44th Place, Suite 100 • Phoenix, AZ 85040 • (888) 979-8669 • Fax: (866) 479-4925

To view the rest of the report, contact a Caris Molecular Intelligence® representative today.

(888) 979- 8669
CustomerSupport@carisls.com

4610 South 44th Place, Suite 100 • Phoenix, AZ 85040 • (888) 979-8669 • Fax: (866) 479-4925